Content area

Abstract

The NLRP3 inflammasome, plays a critical role in the pathogenesis of rheumatoid arthritis (RA) by activating inflammatory cytokines such as IL1β and IL18. Targeting NLRP3 has emerged as a promising therapeutic strategy for RA. In this study, a multidisciplinary approach combining machine learning, quantitative structure–activity relationship (QSAR) modeling, structure–activity landscape index (SALI), docking, molecular dynamics (MD), and molecular mechanics Poisson–Boltzmann surface area MM/PBSA assays was employed to identify novel NLRP3 inhibitors. The ChEMBL database was used to retrieve compounds with known IC50 values to train machine learning (ML) models using the Lazy Predict package. After data pre-processing, 401 non-redundant structures were selected for exploratory data analysis (EDA). PubChem and MACCS fingerprints were used to predict the inhibitory activities of the compounds. SALI was used to identify structurally similar compounds with significantly different biological activities. The compounds were docked using MOE to assess their binding affinities and interactions with key residues in NLRP3. The models were evaluated, and a comparative analysis revealed that the ensemble Random Forest (RF) model (PubChem fingerprints) with RMSE (0.731), R2 (0.622), and MAPE (8.988) and bootstrap aggregating model (MACCS fingerprints) with RMSE (0.687), R2 (0.666), and MAPE (9.216) on the testing set performed well, in accordance with the Organization for Economic Cooperation and Development (OECD) guidelines. Out of all docked compounds, the two most promising compounds (ChEMBL5289544 and ChEMBL5219789) with binding scores of −7.5 and −8.2 kcal/mol were further investigated by MD to evaluate their stability and dynamic behavior within the binding site. MD simulations (200 ns) revealed strong structural stability, flexibility, and interactions in the selected complexes. MM/PBSA binding free energy calculations revealed that van der Waals and electrostatic forces were the key drivers of the binding of the protein with ligands. The outcomes obtained can be used to design more potent and selective NLRP3 inhibitors as therapeutic agents for the treatment of inflammatory diseases such as RA. However, concerns related to the lack of large datasets, experimental validation, and high computational costs remain.

Details

1009240
Business indexing term
Title
Harnessing the Power of Machine Learning Guided Discovery of NLRP3 Inhibitors Towards the Effective Treatment of Rheumatoid Arthritis
Author
Ilyas, Sidra 1   VIAFID ORCID Logo  ; Manan, Abdul 2   VIAFID ORCID Logo  ; Park, Chanyoon 1 ; Hee-Geun Jo 3   VIAFID ORCID Logo  ; Lee, Donghun 1   VIAFID ORCID Logo 

 Department of Herbal Pharmacology, College of Korean Medicine, Gachon University, 1342 Seongnamdae-ro, Sujeong-gu, Seongnam-si 13120, Republic of Korea; [email protected] (S.I.); 
 Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea; [email protected] 
 Department of Herbal Pharmacology, College of Korean Medicine, Gachon University, 1342 Seongnamdae-ro, Sujeong-gu, Seongnam-si 13120, Republic of Korea; [email protected] (S.I.); ; Naturalis Inc. 6, Daewangpangyo-ro, Bundang-gu, Seongnam-si 13549, Republic of Korea 
Publication title
Cells; Basel
Volume
14
Issue
1
First page
27
Publication year
2025
Publication date
2025
Publisher
MDPI AG
Place of publication
Basel
Country of publication
Switzerland
e-ISSN
20734409
Source type
Scholarly Journal
Language of publication
English
Document type
Journal Article
Publication history
 
 
Online publication date
2024-12-30
Milestone dates
2024-11-25 (Received); 2024-12-20 (Accepted)
Publication history
 
 
   First posting date
30 Dec 2024
ProQuest document ID
3153526258
Document URL
https://www.proquest.com/scholarly-journals/harnessing-power-machine-learning-guided/docview/3153526258/se-2?accountid=208611
Copyright
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Last updated
2025-07-23
Database
ProQuest One Academic